Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
417 5 |
Ultima descărcare din IBN: 2024-04-01 23:59 |
Căutarea după subiecte similare conform CZU |
616.33/34-006.3-07-08 (1) |
Patologie. Medicină clinică (6965) |
SM ISO690:2012 CERNAT, Mircea, GHIDIRIM, Nicolae, MIŞIN, Igor, ANTOCI, Lilian, DONSCAIA, Anna, CATRINICI, Victor, GODOROJA, Vitalie, MEDNICOV, Lorena, COROBCEAN, Nadejda, GHERASIM, Mihaela, BACALIM, Lilia, MUSTEAŢĂ, Vasile. Rezultatele utilizării target-terapiei în tratamentul combinat al tumorilor gastrointestinale stromale (GIST). In: Arta Medica , 2016, nr. 3(60), p. 49. ISSN 1810-1852. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Arta Medica | ||||||
Numărul 3(60) / 2016 / ISSN 1810-1852 /ISSNe 1810-1879 | ||||||
|
||||||
CZU: 616.33/34-006.3-07-08 | ||||||
Pag. 49-49 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Introducere. Imatinib mesilat (IM) este utilizat în tratamentul combinat al GIST ca remediu adjuvant sau în combaterea bolii recidivante/metastatice, însă criteriile de selectare a pacienților și a eficacității tratamentului nu sunt clar stabilite. Scop. Evaluarea comparativă a eficacității tratamentului cu IM. Material și metode. Tratament cu IM 400 mg/zi au primit 30/73 (41,1%) pacienți, dintre care tratament adjuvant – 12/30 (40%) (grup I), iar tratament pentru boală recidivantă/metastatică – 18/30 (60%) (grup II). În grupul I, conform clasificării riscului (Miettinen, 2006), 10/12 (83,3%) tumori – cu risc înalt, iar 2/12 (16,7%) – cu risc intermediar. Eficacitatea tratamentului a fost apreciată în baza criteriilor tomodensitometrice Choi (Choi, 2007): răspuns complet (RC); răspuns parțial (RP); stabilizarea bolii (SB); boală progresivă (BP). Rezultate. În grupul I, după administrarea IM în medie 23,4±4,7 luni – nu s-a înregistrat recidiva bolii. În grupul II – RC s-a înregistrat la 3 (16,7%) pacienți, RP la 8 (44,4%), SB ≥6 luni – la 3 (16,7%) și BP la 4 (22,2%) pacienți. Răspuns obiectiv la tratament (RC+RP) – 11 (61,1%) pacienți, control asupra bolii GIST (RC+RP+SB) – la 14 (77,8%), iar progresarea bolii (BP) pe fond de tratament medicamentos – la 4 (22,4%) pacienți. Urmărirea în dinamică – 34,6±3,64 luni. Intervalul de timp până la constatarea progresării bolii GIST în medie – 24,07±2,97 luni. Supraviețuirea ”de facto” la un an a constituit 94,4%, la 2-ani – 83,3% iar la 3-ani – 72,2%. Concluzii. Criteriul major pentru eficiența ”de facto” a terapiei cu IM este lipsa progresării GIST, iar obținerea unui răspuns complet la tratament poate fi indicator indirect al pronosticului favorabil. |
||||||
Cuvinte-cheie tumoră GIST, imatinib mesilat, tratament combinat, GIST tumors, imatinib mesylate, adjuvant treatment |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-129747</cfResPublId> <cfResPublDate>2016-05-01</cfResPublDate> <cfVol>60</cfVol> <cfIssue>3</cfIssue> <cfStartPage>49</cfStartPage> <cfISSN>1810-1852</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/129747</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Rezultatele utilizării target-terapiei în tratamentul combinat al tumorilor gastrointestinale stromale (GIST)</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>tumoră GIST; imatinib mesilat; tratament combinat; GIST tumors; imatinib mesylate; adjuvant treatment</cfKeyw> <cfAbstr cfLangCode='RO' cfTrans='o'><p>Introducere. Imatinib mesilat (IM) este utilizat în tratamentul combinat al GIST ca remediu adjuvant sau în combaterea bolii recidivante/metastatice, însă criteriile de selectare a pacienților și a eficacității tratamentului nu sunt clar stabilite. Scop. Evaluarea comparativă a eficacității tratamentului cu IM. Material și metode. Tratament cu IM 400 mg/zi au primit 30/73 (41,1%) pacienți, dintre care tratament adjuvant – 12/30 (40%) (grup I), iar tratament pentru boală recidivantă/metastatică – 18/30 (60%) (grup II). În grupul I, conform clasificării riscului (Miettinen, 2006), 10/12 (83,3%) tumori – cu risc înalt, iar 2/12 (16,7%) – cu risc intermediar. Eficacitatea tratamentului a fost apreciată în baza criteriilor tomodensitometrice Choi (Choi, 2007): răspuns complet (RC); răspuns parțial (RP); stabilizarea bolii (SB); boală progresivă (BP). Rezultate. În grupul I, după administrarea IM în medie 23,4±4,7 luni – nu s-a înregistrat recidiva bolii. În grupul II – RC s-a înregistrat la 3 (16,7%) pacienți, RP la 8 (44,4%), SB ≥6 luni – la 3 (16,7%) și BP la 4 (22,2%) pacienți. Răspuns obiectiv la tratament (RC+RP) – 11 (61,1%) pacienți, control asupra bolii GIST (RC+RP+SB) – la 14 (77,8%), iar progresarea bolii (BP) pe fond de tratament medicamentos – la 4 (22,4%) pacienți. Urmărirea în dinamică – 34,6±3,64 luni. Intervalul de timp până la constatarea progresării bolii GIST în medie – 24,07±2,97 luni. Supraviețuirea ”de facto” la un an a constituit 94,4%, la 2-ani – 83,3% iar la 3-ani – 72,2%. Concluzii. Criteriul major pentru eficiența ”de facto” a terapiei cu IM este lipsa progresării GIST, iar obținerea unui răspuns complet la tratament poate fi indicator indirect al pronosticului favorabil.</p></cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Introduction. Imatinib mesylate (IM) is used as adjuvant treatment in GIST or as therapy of recurrent/metastatic disease, but the criteria for patient selection and efficacy of treatment are not clearly established. Purpose. Comparative evaluation of efficacy of IM. Material and methods. Treatment with IM 400mg/day received 30/73 (41.1%) patients, including adjuvant therapy 12/30 (40%) (Ist group), and treatment of recurrent/metastatic disease – 18/30 (60%) (IInd group). According to Miettinen risk classification (Miettinen, 2006) – 10/12 (83.3%) tumors were of high risk and 2/12 (16.7%) – of intermediate risk. Efficacy of the treatment was assessed using CT Choi criteria (Choi, 2007): complete response (CR), partial response (PR), stable disease (SD), progression of disease (PD). Results. In the Ist group, after administration of IM for a median period of 23.4±4.7 months – no recurrence of the disease was recorded. In the IInd group – CR was assessed in 3 (16.7%) patients, PR – in 8 (44.4%), SD ≥6 months – in 3 (16.7%) and PD in 4 (22.2%) patients. Objective response to treatment (CR+PR) was recorded in 11 (61.1%) patients, control of the disease (CR+PR+SD) – in 14 (77.8%), and progression of the disease – in 4 (22.4%) patients. Median follow-up time was 34.6±3.64 months. Median time to progression of the disease was 24.07±2.97 months. 1-year survival rate was 94.4%, 2-year survival rate – 83.3% and 3-year survival rate – 72.2%. Conclusion. The major criteria for effectiveness of IM therapy is the lack of GIST progression and achieving a complete response to treatment may be an indirect indicator of favorable prognosis</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-27276</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11719</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11744</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10637</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11707</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10770</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-26648</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-15967</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-46299</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-43043</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-43134</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11430</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-27276</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-27276-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Чернат</cfFamilyNames> <cfFirstNames>Мирча</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11719</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11719-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Гидирим</cfFamilyNames> <cfFirstNames>Николае</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11744</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11744-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Mishin</cfFamilyNames> <cfFirstNames>Igor</cfFirstNames> <cfFamilyNames>Мишин</cfFamilyNames> <cfFirstNames>Игорь</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10637</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10637-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Анточ</cfFamilyNames> <cfFirstNames>Лилиан</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11707</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11707-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Донская </cfFamilyNames> <cfFirstNames>Анна</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10770</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10770-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Катринич</cfFamilyNames> <cfFirstNames>В.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-26648</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-26648-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Годорожа</cfFamilyNames> <cfFirstNames>Виталий</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-15967</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-15967-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Медникова</cfFamilyNames> <cfFirstNames>Л.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-46299</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-46299-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Коробчан</cfFamilyNames> <cfFirstNames>Надежда</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-43043</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-43043-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Герасим</cfFamilyNames> <cfFirstNames>Михаела</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-43134</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-43134-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Бакалым</cfFamilyNames> <cfFirstNames>Лилия</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11430</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11430-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-05-01T24:00:00</cfStartDate> <cfFamilyNames>Musteaţă</cfFamilyNames> <cfFirstNames>Vasile</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>